200,000+ products from a single source!
sales@angenechem.com
Home > Fluorides > 259525-01-4
259525-01-4 | Pyrimidine, 4-(4-fluorophenyl)-2-methyl-6-[[5-(1-piperidinyl)pentyl]oxy]-
CAS No: 259525-01-4 Catalog No: AG002R6M MDL No:
Product Description
Catalog Number:
AG002R6M
Chemical Name:
Pyrimidine, 4-(4-fluorophenyl)-2-methyl-6-[[5-(1-piperidinyl)pentyl]oxy]-
CAS Number:
259525-01-4
Molecular Formula:
C21H28FN3O
Molecular Weight:
357.4649
IUPAC Name:
4-(4-fluorophenyl)-2-methyl-6-(5-piperidin-1-ylpentoxy)pyrimidine
InChI:
InChI=1S/C21H28FN3O/c1-17-23-20(18-8-10-19(22)11-9-18)16-21(24-17)26-15-7-3-6-14-25-12-4-2-5-13-25/h8-11,16H,2-7,12-15H2,1H3
InChI Key:
SZSHJTJCJOWMHM-UHFFFAOYSA-N
SMILES:
Fc1ccc(cc1)c1cc(OCCCCCN2CCCCC2)nc(n1)C
UNII:
VR034VW8OG
Properties
Complexity:
384
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
357.222g/mol
Formal Charge:
0
Heavy Atom Count:
26
Hydrogen Bond Acceptor Count:
5
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
357.473g/mol
Monoisotopic Mass:
357.222g/mol
Rotatable Bond Count:
8
Topological Polar Surface Area:
38.2A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
4.6
Literature
| Title | Journal |
|---|---|
| Decreasing the infusion rate reduces the proarrhythmic risk of NS-7: confirming the relevance of short-term variability of repolarisation in predicting drug-induced torsades de pointes. | British journal of pharmacology 20050601 |
| NS-7, a novel Na+/Ca2+ channel blocker, prevents neurologic injury after spinal cord ischemia in rabbits. | The Journal of thoracic and cardiovascular surgery 20050201 |
| Neuroprotective effect of the novel Na+/Ca2+ channel blocker NS-7 on rat retinal ganglion cells. | Japanese journal of ophthalmology 20050101 |
| Neuroprotective effect of NS-7, a novel Na+ and Ca2+ channel blocker, in a focal ischemic model in the rat. | Brain research 20030418 |
| Cardiac electrophysiological modulation by NS-7, a novel neuroprotective drug, of guinea pig ventricular muscles. | Life sciences 20030117 |
| Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. | Arzneimittel-Forschung 20030101 |
| Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 2nd communication: tissue distributions, placental transfer and milk secretion of radioactivity after a single intravenous 14C-NS-7 injection to rats. | Arzneimittel-Forschung 20030101 |
| A novel voltage-sensitive Na(+) and Ca(2+) channel blocker, NS-7, prevents suppression of cyclic AMP-dependent protein kinase and reduces infarct area in the acute phase of cerebral ischemia in rat. | Brain research 20020104 |
| Electrophysiological and neurochemical evidence for voltage-dependent Ca(2+) channel blockade by a novel neuroprotective agent NS-7. | Pharmacology & toxicology 20010901 |
| Reversal by NS-7, a neuroprotective compound, of the decrease in transcription factor CREB mRNA expression in rat brain after permanent middle cerebral artery occlusion. | Neuroscience letters 20010615 |
| Effective plasma concentration of a novel Na+/Ca2+ channel blocker NS-7 for its cerebroprotective actions in rats with a transient middle cerebral artery occlusion. | The Journal of pharmacology and experimental therapeutics 20010201 |
| Cerebroprotective action of a Na+/Ca2+ channel blocker NS-7. I. Effect on the cerebral infarction and edema at the acute stage of permanent middle cerebral artery occlusion in rats. | Brain research 20010126 |
| Cerebroprotective action of a Na+/Ca2+ channel blocker NS-7. II. Effect on the cerebral infarction, behavioral and cognitive impairments at the chronic stage of permanent middle cerebral artery occlusion in rats. | Brain research 20010126 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.